John R. Fozard

John R. Fozard's AcademicInfluence.com Rankings

John R. Fozard

Medical

#2502

World Rank

#2929

Historical Rank

Pharmacology

#261

World Rank

#307

Historical Rank

medical Degrees

Download Badge

Medical

John R. Fozard's Degrees

PhD Pharmacology University of Washington
Bachelors Pharmacy University of Washington

Why Is John R. Fozard Influential?

(Suggest an Edit or Addition)

(See a Problem?)

John R. Fozard's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). (1994) (3115)
Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine (1986) (1250)
8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5-HT1 recognition site. (1983) (854)
The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat. (1984) (677)
Neuronal 5-HT receptors in the periphery (1984) (320)
The 5-HT4 receptor: a place in the sun. (1992) (240)
L-Ornithine decarboxylase:an essential role in early mammalian embryogenesis. (1980) (229)
Cardiovascular Response to 8-Hydroxy-2-(di-n-Propylamino) Tetralin (8-OH-DPAT) in the Rat: Site of Action and Pharmacological Analysis (1987) (206)
Regional vasodilation is a prominent feature of the haemodynamic response to endothelin in anaesthetized, spontaneously hypertensive rats. (1988) (196)
Mechanism of the Hypotensive Effect of Ketanserin (1982) (176)
5-HT: The Enigma Variations (1987) (172)
The Peripheral actions of 5-hydroxytryptamine (1989) (160)
In Vitro and in Vivo Pharmacological Characterization of 5-[(R)-2-(5,6-Diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (Indacaterol), a Novel Inhaled β2 Adrenoceptor Agonist with a 24-h Duration of Action (2006) (157)
Subtypes of the type 4 cAMP phosphodiesterases: structure, regulation and selective inhibition. (1996) (153)
MECHANISM OF THE INDIRECT SYMPATHOMIMETIC EFFECT OF 5‐HYDROXYTRYPTAMINE ON THE ISOLATED HEART OF THE RABBIT (1976) (149)
The 5-HT4 receptor: naughty, but nice. (1989) (149)
Graphics computer-aided receptor mapping as a predictive tool for drug design: development of potent, selective, and stereospecific ligands for the 5-HT1A receptor. (1988) (143)
Blockade of neuronal tryptamine receptors by metoclopramide. (1978) (143)
Serotonin: Molecular Biology, Receptors and Functional Effects (1991) (136)
Subtypes of the 5-HT receptor mediating the behavioural responses to 5-methoxy-N,N-dimethyltryptamine in the rat. (1985) (135)
Mast cell degranulation following adenosine A3 receptor activation in rats. (1996) (130)
Adenosine A3 receptors 1 mediate hypotension in the angiotensin II‐supported circulation of the pithed rat (1993) (123)
A role for mast cells in adenosine A3 receptor‐mediated hypotension in the rat (1995) (121)
Evidence that the putative 5-HT1A receptor agonists, 8-OH-DPAT and ipsapirone, have a central hypotensive action that differs from that of clonidine in anaesthetised cats. (1987) (117)
Effects of CGS 21680, a selective adenosine A2A receptor agonist, on allergic airways inflammation in the rat. (2002) (115)
Mediation of the discriminative stimulus properties of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) by the putative 5-HT1A receptor. (1987) (107)
Blockade of serotonin receptors on autonomic neurones by (-)-cocaine and some related compounds. (1979) (103)
A role for sensory nerves in the late asthmatic response (2011) (100)
MDL 72222: a potent and highly selective antagonist at neuronal 5-hydroxytryptamine receptors (1984) (97)
Adenosine receptor ligands: potential as therapeutic agents in asthma and COPD. (1999) (94)
The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. (2010) (85)
Role of histamine in tumor development (1985) (79)
The animal pharmacology of drugs used in the treatment of migraine (1975) (78)
5-HT1C receptor activation: a key step in the initiation of migraine? (1989) (77)
Pharmacological properties of dolasetron, a potent and selective antagonist at 5‐HT3 receptors (1993) (76)
Inhibition of murine embryonic development by alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase. (1980) (75)
Assay of α-difluoromethylornithine in body fluids and tissues by automatic amino-acid analysis (1981) (71)
MRI of lung parenchyma in rats and mice using a gradient‐echo sequence (2001) (69)
5-HT3 receptors and cytotoxic drug-induced vomiting (1987) (68)
Mechanism of airway hyperresponsiveness to adenosine induced by allergen challenge in actively sensitized Brown Norway rats (2001) (66)
Adenosine-mediated mast cell degranulation in adenosine deaminase-deficient mice. (2001) (63)
Haemodynamic responses to NG‐monomethyl‐l‐arginine in spontaneously hypertensive and normotensive Wistar‐Kyoto rats (1991) (62)
The case for a role for adenosine in asthma: almost convincing? (2003) (57)
Pulmonary inflammation monitored noninvasively by MRI in freely breathing rats. (2002) (56)
MDL 72832: a potent and stereoselective ligand at central and peripheral 5-HT1A receptors. (1988) (55)
Radioligand binding study of a series of 5-HT1A receptor agonists and definition of a steric model of this site (1989) (53)
Agonists and antagonists of 5-HT3 receptors (1990) (53)
Noninvasive detection of endotoxin-induced mucus hypersecretion in rat lung by MRI. (2002) (53)
SDZ 216-525, a selective and potent 5-HT1A receptor antagonist. (1993) (52)
5-Hydroxytryptamine (5-HT) and the initiation of migraine: new perspectives (1994) (51)
Effects on Migraine Headache of MDL 72,222, an Antagonist at Neuronal 5-HT Receptors. Double-Blind, Placebo-Controlled Study (1985) (47)
(E)-2-(3,4-dimethoxyphenyl)-3-fluoroallylamine: a selective, enzyme-activated inhibitor of type B monoamine oxidase. (1984) (45)
Adenosine receptor ligands as potential therapeutics in asthma. (2002) (44)
Resolution of the oedema associated with allergic pulmonary inflammation in rats assessed noninvasively by magnetic resonance imaging (2003) (43)
Lung inflammation and vascular remodeling after repeated allergen challenge detected noninvasively by MRI. (2007) (43)
Functional correlates of 5-HT1 recognition sites (1983) (43)
Antagonist pharmacology of adenosine A2B receptors from rat, guinea pig and dog. (2003) (39)
The 5-hydroxytryptamine-nitric oxide connection: the key link in the initiation of migraine? (1995) (39)
BW-A522 blocks adenosine A3 receptor-mediated hypotensive responses in the rat. (1994) (38)
Basic mechanisms of antimigraine drugs. (1982) (37)
Comparative effects of four migraine prophylactic drugs on an isolated extracranial artery. (1976) (36)
The hypotensive action of 5-hydroxytryptamine (5-HT) in anaesthetised and pithed rats. (1968) (35)
Antihypertensive effects of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in conscious dogs. (1988) (34)
Capsaicin‐induced mucus secretion in rat airways assessed in vivo and non‐invasively by magnetic resonance imaging (2007) (34)
Further pharmacological characterization of the adenosine receptor subtype mediating inhibition of oxidative burst in human isolated neutrophils (1998) (33)
Adenosine A3 receptors: two into one won't go. (1993) (33)
Effects of wortmannin on airways inflammation induced by allergen in actively sensitised Brown Norway rats. (2001) (32)
A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potential. (2005) (31)
Sphingosine-1-Phosphate-Induced Airway Hyper-Reactivity in Rodents Is Mediated by the Sphingosine-1-Phosphate Type 3 Receptor (2012) (30)
MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease (1989) (29)
Techniques: magnetic resonance imaging of the lung provides potential for non-invasive preclinical evaluation of drugs. (2003) (29)
Pharmacological consequences of inhibition of polyamine biosynthesis with DL-α-difluoromethyl-ornithine (1982) (29)
Contraction of the rat isolated spleen mediated by adenosine A1 receptor activation (1993) (29)
Comparison of the anti-bronchoconstrictor activities of inhaled formoterol, its (R,R)- and (S,S)-enantiomers and salmeterol in the rhesus monkey. (2001) (28)
Differences between receptors for 5-hydroxytryptamine on autonomic neurones revealed by nor-(-)-cocaine. (1983) (28)
Species differences in bradykinin receptor-mediated responses of the airways. (2002) (28)
Control of heparinisation during cardiopulmonary bypass (1980) (27)
5-HT in migraine: evidence from 5-HT receptor antagonists for a neuronal aetiology (1990) (27)
Evidence for an atypical receptor mediating the augmented bronchoconstrictor response to adenosine induced by allergen challenge in actively sensitized Brown Norway rats (2002) (27)
Salbutamol-induced airway hyperreactivity in guinea pigs is not due to a loss of its bronchodilator effect. (1995) (24)
Dual and selective antagonism of neurokinin NK1 and NK2 receptor-mediated responses in human colon mucosa (2003) (24)
Identification with MRI of the pleura as a major site of the acute inflammatory effects induced by ovalbumin and endotoxin challenge in the airways of the rat. (2006) (24)
In Vitro and in Vivo Pharmacological Characterization of 5-[ ( R )-2-( 5 , 6-Diethyl-indan-2-ylamino )-1-hydroxyethyl ]-8-hydroxy-1 H-quinolin-2one ( Indacaterol ) , a Novel Inhaled 2 Adrenoceptor Agonist with a 24h Duration of Action (2006) (24)
An investigation into the structure-activity relationships associated with the systematic modification of the β(2)-adrenoceptor agonist indacaterol. (2012) (24)
Monoamine receptor sensitivity changes following chronic administration of MDL 72394, a site-directed inhibitor of monoamine oxidase. (1986) (23)
5-HT1 receptor agonists attenuate the naloxone-induced jumping behaviour in morphine-dependent mice. (1989) (22)
Ovarian function in the rat following irreversible inhibition of L-ornithine decarboxylase. (1980) (22)
Effect of pertussis toxin treatment on the putative adenosine A3 receptor-mediated hypotensive response in the rat. (1993) (21)
The novel 5‐HT1A receptor antagonist, SDZ 216–525, decreases 5‐HT release in rat hippocampus in vivo (1993) (21)
Airway hyperresponsiveness to bradykinin induced by allergen challenge in actively sensitised Brown Norway rats (2004) (21)
The rational design of suicide substrates of amine oxidases. (1986) (21)
Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate. (2012) (21)
New highly potent and selective adenosine A(3) receptor antagonists. (2004) (20)
Depression of Sympathetic Nervous Function by DL‐α‐Monofluoromethyldopa, an Enzyme‐Activated, Irreversible Inhibitor of L‐Aromatic Amino Acid Decarboxylase (1980) (20)
KCO912: a potent and selective opener of ATP-dependent potassium (KATP) channels which suppresses airways hyperreactivity at doses devoid of cardiovascular effects (2002) (20)
The receptor mechanism mediating the contractile response to adenosine on lung parenchymal strips from actively sensitised, allergen-challenged Brown Norway rats (2005) (19)
Blockade of the flare response to intradermal 5-hydroxytryptamine in man by MDL 72.222, a selective antagonist at neuronal 5-hydroxytryptamine receptors (2004) (18)
KATP channel openers for the treatment of airways hyperreactivity. (1999) (18)
SCA 40: studies of the relaxant effects on cryopreserved human airway and vascular smooth muscle (1997) (18)
Effects of a mitogen-activated protein kinase inhibitor on allergic airways inflammation in the rat studied by magnetic resonance imaging. (2003) (18)
Chapter 5. Drugs Acting at Central 5-Hydroxytryptamine Receptors (1986) (18)
5-HT in nervous system disease and migraine. (1992) (17)
Synthesis and biological properties of novel glucocorticoid androstene C-17 furoate esters. (2004) (16)
Effects of immunomodulators on airways hyperresponsiveness to adenosine induced in actively sensitised Brown Norway rats by exposure to allergen (2003) (14)
Role of sphingosine-1-phosphate (S1P) and the S1P2 receptor in allergen-induced, mast cell-dependent contraction of rat lung parenchymal strips (2009) (14)
A locally active antiinflammatory macrolide (MLD987) for inhalation therapy of asthma. (2004) (13)
Airway hyperresponsiveness to adenosine induced by lipopolysaccharide in Brown Norway rats (2002) (13)
Assay of alpha-difluoromethylornithine in body fluids and tissues by automatic amino-acid analysis. (1981) (13)
Progress towards novel adenosine receptor therapeutics gleaned from the recent patent literature (2010) (13)
A useful muscarinic parameter and the differential recording of atrial and ventricular tension in the perfused rabbit heart (2005) (13)
No major role for atrial natriuretic peptide in the vasodilator response to endothelin-1 in the spontaneously hypertensive rat. (1990) (13)
Metoclopramide antagonism of 5-hydroxytryptophan-induced “Wet-Dog” shake behaviour in the rat (1979) (12)
Failure of 5-methoxytryptamine to evoke the Bezold-Jarisch effect supports homology of excitatory 5-HT receptors on vagal afferents and postganglionic sympathetic neurones. (1983) (12)
The depolarizing action of 5-hydroxytryptamine on rabbit vagal primary afferent and sympathetic neurones and its selective blockade by MDL 72222 (1985) (12)
Further Definition of the 5-HT Receptor Mediating Contraction of Rat Stomach Fundus: Relation to 5-HT 1D Recognition Sites (1991) (12)
5-Hydroxytryptamine in central cardiovascular regulation (1990) (11)
Interaction between adenosine and allergen or compound 48/80 on lung parenchymal strips from actively sensitized Brown Norway rats. (2004) (11)
Hypotensive responses to the putative adenosine A3 receptor agonist N6‐2‐(4‐aminophenyl)‐ethyladenosine in the rat (1993) (11)
8-OH-DPAT: an enigmatic centrally active 5-HT agonist (1984) (11)
Anaesthesia and familial hypokalaemic periodic paralysis (1983) (11)
Dual mechanism of the stimulant action of N,N-dimethyl-5-hydroxy-tryptamine (bufotenine) on cardiac sympathetic nerves. (1978) (11)
9 – The Contragestational Effects of Ornithine Decarboxylase Inhibition (1987) (11)
Effects of wortmannin on bronchoconstrictor responses to adenosine in actively sensitised Brown Norway rats. (2000) (10)
Suppression of Adenosine A3 Receptor-Mediated Hypotension and Mast Cell Degranulation in the Rat by Dexamethasone (2002) (10)
Atrial sympathetic nerves after perfusion of the rabbit heart with low sodium solutions containing potassium chloride or urea—a biochemical, histochemical and fine structural study (1978) (10)
Lack of modulation by presynaptic alpha 2-adrenoceptors of adrenergic transmitters release evoked by activation of 5-hydroxytryptamine and nicotine receptors. (1981) (10)
Synthesis and evaluation of two series of 4'-aza-carbocyclic nucleosides as adenosine A2A receptor agonists. (2010) (10)
Effects of several muscarinic agonists on cardiac performance and the release of noradrenaline from the sympathetic nerves of the rabbit heart. (1971) (9)
From Hypertension (+) to Asthma: Interactions with the Adenosine A 3 Receptor from a Personal Perspective (2010) (9)
Potassium Channel Openers Agents for the Treatment of Airway Hyperreactivity (2001) (9)
Effects of progesterone on cardiovascular responses to amines and to sympathetic stimulation in the pithed rat (1971) (9)
Stereoselective preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a potent and orally active dual neurokinin NK(1)/NK(2) receptor antagonist. (2003) (9)
Effect of the K+(ATP) channel opener, KCO912, on baseline and allergen induced airway hyperresponsiveness in allergic rabbits. (2004) (8)
The mode of action of ketanserin (1983) (8)
Inhibition by viozan of extravasation induced in rat trachea by capsaicin is mediated exclusively by β2-adrenoceptors (2001) (8)
The cardiovascular effects of selective adenosine A1 and A2 receptor agonists in the pithed rat: no role for glibenclamide-sensitive potassium channels (1993) (8)
Drug induced changes in the distribution of 14C5-HT in the pithed reserpinized rat. (1969) (8)
Interactions between antimigraine drugs and a high affinity uptake and storage mechanism for 5-hydroxytryptamine. (1976) (7)
Effects of DL-alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, on the rat mammary tumour induced by 7,12-dimethylbenz[a]anthracene. (1982) (7)
The billion-dollar battle: Merck v Glaxo: Matthew Lynn, Heinemann, 1991. £16.99 (244 pages) ISBN 0 434 43924 X (1992) (7)
Carruthers and Fozard reply (1994) (7)
The Development of 5-HT3 Receptor Antagonists (1989) (7)
A randomised, single blind study to evaluate the effects of action potential simulator therapy compared with placebo in patients with chronic back pain (2002) (7)
Comparison between the cardiovascular effects of 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) and clonidine in the conscious sino-aortic denervated rat. (1988) (7)
Evidence for tryptamine receptors on cardiac sympathetic nerves [proceedings]. (1976) (7)
A controlled clinical trial of oral droperidol and droperidol plus diazepam for premedication in children. (1977) (6)
Enhancement of ovulation in the rat by DL-alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase. (1982) (6)
Inhibition of early embryogenic development in mice by alpha-difluoromethyl ornithine, an enzyme-activated irreversible inhibitor of L-ornithine decarboxylase [proceedings]. (1979) (6)
Modeling the response of the asthmatic airways to adenosine: Mechanisms and receptors (2003) (6)
The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties ofl-deprenyl and MDL 72145 (1985) (6)
Lung MRI in Small Rodents as a Tool for the Evaluation of Drugs in Models of Airways Diseases (2006) (6)
Selective blockade of presynaptic tryptamine receptors by (-)-cocaine and (+)-cocaine [proceedings]. (1977) (6)
Mechanism of the Antihypertensive Action of DL-α-Monofluoromethyldopa: Implications for the Role of the Sympathetic Nervous System in Maintenance of Elevated Blood Pressure in Spontaneously Hypertensive Rats (1981) (6)
Do adrenergic fibres have muscarinic inhibitory receptors?—a reply (1974) (5)
(E)-2-(3,4-DIMETHOXYPHENYL)-3-FLUOROALLYLAMINE: A SELECTIVE, ENZYME-ACTIVATED INHIBITOR OF TYPE B MONOAMINE OXIDASE (1984) (5)
697 – THE STIMULANT RESPONSE OF 5-HYDROXYTRYPTAMINE ON CARDIAC SYMPATHETIC NERVES: RESISTANCE TO BLOCKADE BY CLASSICAL TRYPTAMINE RECEPTOR ANTAGONISTS (1977) (5)
A3 Adenosine Receptor Regulation of Cells of the Immune System and Modulation of Inflammation (2010) (5)
5-HT3 Receptors (1990) (4)
Proceedings: Chemical sympathectomy of the rabbit with 6-hydroxydopamine. (1973) (4)
Cardiovascular effects of cyclosporine A and OG 37-325 after chronic administration to conscious rats: role of endothelin. (1994) (4)
Suxamethonium pains and electromyograph recordings in children. (1977) (4)
Blockade of Neuronal 5-Hydroxytryptamine Receptors with MDL 72222 (1985) (4)
Central 5-hydroxytryptamine (5-HT) and its effect on the cardiovascular system (1990) (4)
Muscarinic inhibition of the release of the adrenergic transmitter from peripheral sympathetic fibres. (1973) (4)
The airways pharmacology of DNK333, a potent, selective, non‐peptide dual NK1/NK2 receptor antagonist (2004) (4)
Lack of a role for blood platelets in the uptake of 5-hydroxytryptamine by the rabbit heart. (1974) (3)
Cardiovascular effects of endothelin 1 in pithed spontaneously hypertensive rats: evaluation of its mechanism(s) of action (1989) (3)
5-HT1A Receptors and Cardiovascular Control (1989) (3)
Stimulant effects of 5-hydroxytryptamine on cardiac sympathetic nerves. (1975) (3)
The effects of reserpine on the distribution of [14C]5‐hydroxytryptamine in the rat (1969) (3)
Single nucleotide polymorphism analysis of the human adenosine A2B receptor gene: Prevalence of SNPs in asthmatics and normal subjects (2002) (3)
Suppression of histamine-induced tachypnoea in the rhesus monkey by sibenadet: no role for dopamine D2 receptors. (2004) (2)
The identification of 7-[(R)-2-((1S,2S)-2-benzyloxycyclopentylamino)-1-hydroxyethyl]-4-hydroxybenzothiazolone as an inhaled long-acting β2-adrenoceptor agonist. (2014) (2)
5-HT autopotentiation and drug induced changes in the 5-HT vasomotor response in the pithed rat. (1969) (2)
Anti‐bronchoconstrictor activities and side effect potential of inhaled formoterol and (S,R)‐epiformoterol in the rhesus monkey (2002) (2)
Graphics computer-generated receptor mapping as a redictive tool for drug design (1986) (2)
Effects of endotoxin and allergen alone and in combination on the sensitivity of the rat airways to adenosine. (2005) (2)
The uptake of 5-hydroxytryptamine by the rabbit heart in vitro. (1973) (2)
Haemodynamic effects of NG-monomethyl-L-arginine (L-NMMA) in anaesthetized, spontaneously hypertensive (SH) rats: comparison with normotensive wistar-kyoto (WKY) controls (1990) (1)
Effects of dl-α-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase, on the rat mammary tumour induced by 7,12-dimethylbenz[a]anthracene (1982) (1)
Mechanism of the attenuation of naloxone induced jumping behavior in morphine dependent mice by 5 ht 1 receptor agonists (1988) (1)
S.18.04 Neurotherapeutic potential of 5-HT3 receptor antagonists (1996) (1)
Airways pharmacology of DNK333A, a dual NK1/NK2 neurokinin receptor antagonist (2002) (1)
Adenosine A3receptors' mediate hypotension intheangiotensin Il-supported circulation ofthepithed rat (1993) (1)
Inhibition of 5-hydroxytryptamine-evoked autonomic transmitter release by apomorphine. (1982) (1)
Magnetic Resonance Imaging (MRI) of the Lung as a Tool for the Non-Invasive Evaluation of Drugs in Rat Models of Airways Diseases (2005) (1)
2033 – INVESTIGATION OF THE ANTAGONISM BY APOMORPHINE OF THE SYMPATHOMIMETIC RESPONSE TO 5-HT IN PERFUSED RABBIT HEART (1978) (1)
ANXIOGENIC AGENTS INCREASE TRIBULIN CONCENTRATIONS IN RAT BRAIN AND HEART (2007) (1)
Structure-activity relationship of compounds which block receptors for 5-hydroxytryptamine on the sympathetic nerves of the rabbit heart [proceedings]. (1977) (0)
Two kinds of tryptamine receptor (1997) (0)
Identification of human serum cholinesterase variants using the polyrnerase chain reaction amplification technique (2002) (0)
Use of the quinolizin and quinolizinone derivatives in the manufacture of pharmaceutical (1989) (0)
Use of the quinolizin and quinolizinone derivatives in the manufacture of medicinal products (1989) (0)
[34] Methods for the study of the experimental interruption of pregnancy by ornithine decarboxylase inhibitors: Effects of dl-α-difluoromethylornithine (1983) (0)
Methods for the study of the experimental interruption of pregnancy by ornithine decarboxylase inhibitors: effects of DL-alpha-difluoromethylornithine. (1983) (0)
Lack of a role for cardiac sympathetic nerves in the uptake and metabolism of 3H-5-hydroxytryptamine by isolated rabbit hearts. (1975) (0)
human adenosine A 2B receptor gene: prevalence (2002) (0)
Differential sensitivity of neuronal stimulant responses to 5-hydroxytryptamine to inhibition by agonists at presynaptic receptor sites [proceedings]. (1977) (0)
Slide-tape programmes in the teaching of pharmacology [proceedings]. (1976) (0)
Spasmogen release from an extracranial vascular bed evoked by neurohumoral stimuli and periods of vascular stasis. (1978) (0)
Ultrastructural changes in atrial sympathetic nerves during perfusion with solutions deficient in sodium and compensated by potassium or urea [proceedings]. (1977) (0)
Bonny baby (1993) (0)
5-Hydroxytryptamine (5-HT) receptors in migraine (1996) (0)
Discovery of long acting inhaled muscarinic M3 receptor antagonists (2007) (0)
Metoclopramide antagonism of 5-hydroxytryptophan-induced 'wet-dog' shake behaviour in the rat [proceedings]. (1978) (0)
Use of quinolizine and quinolizinone derivatives for producing medicaments. (1989) (0)
Use of quinolizine and quinolizine derivative in case of production of medicine (1989) (0)
Evidence for trypta mine receptors on cardiac sympathetic nerves (2006) (0)
Controversies in respiratory diseases and their management. (2003) (0)
Inhibition of peripheral sympathetic function by alpha-monofluoromethyldopa, an irreversible inhibitor of aromatic amino acid decarboxylase [proceedings]. (1979) (0)
Inhibition of the stimulant effect of 5-hydroxytryptamine on cardiac sympathetic nerves by 5-hydroxytrptamine and related compounds [proceedings]. (1976) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With John R. Fozard?

John R. Fozard is affiliated with the following schools:

University of Manchester